Investment Rating - The investment rating for the company is "Buy" (maintained) for both A-shares and H-shares [6]. Core Views - The company reported a net profit of RMB 46.2 billion for 2025, representing a year-on-year growth of 9.6%, which is below previous expectations of RMB 53.8 billion. Both life insurance and property insurance segments underperformed [1]. - The new business value (NBV) for life insurance grew by 41% year-on-year, driven primarily by the strong performance of life insurance through bank channels. The company expects a 24% growth in NBV for 2026 [2]. - The combined ratio (COR) for property insurance improved to 97.5%, a year-on-year improvement of 1.3 percentage points, with underwriting profit soaring by 119.4% to RMB 12.535 billion [3]. - The net investment yield for 2025 was 3.5%, a decrease of 0.4 percentage points year-on-year, while the total investment return rate remained stable at 5.6% [4]. - The company has adjusted its earnings per share (EPS) forecasts for 2026, 2027, and 2028 to RMB 1.20, RMB 1.31, and RMB 1.45, respectively, and has lowered the target price based on DCF valuation to RMB 10.00 for A-shares and HKD 8.00 for H-shares [5]. Summary by Sections Life Insurance - The life insurance segment's NBV increased by 41% year-on-year, with individual life insurance and health insurance NBV growing by 65% and 23%, respectively. The company lowered the discount rate for participating and universal life insurance to 7.5% from 8.5% [2]. Property Insurance - The property insurance segment's COR improved to 97.5%, with a significant underwriting profit increase. The COR for auto insurance was 95.3%, reflecting a 1.5 percentage point improvement, primarily due to a substantial decrease in expense ratios [3]. Investment Performance - The company maintained a total investment return rate of 5.6% despite a decline in net investment yield. The net assets grew by 15% year-on-year, indicating strong capital strength [4]. Profit Forecast and Valuation - The company has revised its EPS forecasts downward for the next three years and adjusted the target price based on DCF valuation methods. The new target prices are RMB 10.00 for A-shares and HKD 8.00 for H-shares [5].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown impressive growth in new business value (NBV), driven by its bancassurance channel, with a projected NBV growth of 23.0% in 2026 [1] - The company is expected to maintain double-digit growth in operating profit, supported by its strong bancassurance channel and low valuation [1] - The forecast for the company's net profit for 2026-2028 has been adjusted to 148.1 billion, 161.4 billion, and 176.2 billion respectively, reflecting a year-on-year growth of 9.9%, 9.0%, and 9.2% [1] Financial Performance Summary - In 2025, the group's net profit attributable to the parent company is projected to be 143.8 billion, a year-on-year increase of 22.5% [1] - The operating profit for the group is expected to reach 134.4 billion, with a year-on-year growth of 10.3% [1] - The embedded value (EV) for the group and life insurance segment is projected to be 1.50 trillion and 0.93 trillion respectively, with year-on-year increases of 5.7% and 11.2% [1] - The new business value (NBV) for life and health insurance is expected to reach 369 billion in 2025, reflecting a year-on-year growth of 29.3% [2] - The company plans to distribute a cash dividend of 2.7 yuan per share, a year-on-year increase of 5.9%, resulting in a current dividend yield of 4.7% [1] Investment Strategy and Asset Allocation - The company has significantly increased its equity allocation, with equity assets accounting for 20% of its investment portfolio by the end of 2025, up from 11% at the beginning of the year [3] - The total investment income for the year is projected to be 234.3 billion, with an overall investment return rate of 3.6% [3] - The company has optimized its cost of risk (COR) and improved its underwriting performance, with a combined ratio of 96.8% in 2025, a decrease of 1.5 percentage points year-on-year [3]

Group 1 - The core view of the report indicates that the A-share insurance industry is expected to return to a P/EV of 1x, with both asset and liability sides flourishing, driven by a recovery in EV growth and favorable interest rate conditions [3][4][36] - The report anticipates a long-term EV growth rate returning to double digits, with a focus on opportunities for long-term interest rates to break through the 2.0% threshold [3][36] - The insurance sector is expected to benefit from a gradual recovery in the equity market, which will enhance the investment ecosystem for insurance capital [6][39] Group 2 - In the life insurance sector, the report highlights a comprehensive and sustained widening of profit sources, with a positive outlook for the 2026 performance driven by asset reallocation and a gradual bull market in equities [4][36] - The non-auto insurance sector is set to improve underwriting profitability through a regulatory shift towards quality enhancement, with a projected increase in underwriting profit of approximately 5.8 billion yuan if profit margins improve by 1 percentage point [5][36] - The report suggests that the insurance companies are likely to maintain double-digit growth in core premium income and value growth in 2026, supported by effective channel expansion and improved sales dynamics [4][52] Group 3 - The report emphasizes the importance of the investment strategy, noting that the current low interest rate environment necessitates a focus on equity investments to enhance returns [6][39] - It is projected that the average EV growth for listed insurance companies will be 10.6%, 10.9%, and 10.8% from 2025 to 2027, with NBV growth rates of 34.7%, 21.7%, and 10.0% respectively [36][37] - The report indicates that the insurance sector's valuation is expected to gradually approach 1x P/EV as long-term interest rates stabilize and improve [39][40]

Investment Rating - The investment rating for the company is "Buy" [8][6]. Core Views - The company reported a steady growth in New Business Value (NBV) of 20% year-on-year for 1H25, despite a decline in pre-tax profit by 11.5% [2][6]. - The interim dividend increased by 19% to RMB 0.24, outpacing profit growth [1]. - The annualized net investment return decreased to 2.78%, while the total investment return fell to 3.29% [4]. Summary by Sections Financial Performance - The earnings per share (EPS) for 1H25 was RMB 1.45, a 6.9% increase year-on-year, primarily due to a significant reduction in income tax expenses [1]. - The NBV for 1H25 showed a 20% increase on a comparable basis, indicating robust growth compared to peers [2]. - The company’s net assets increased by 2.8% year-to-date, and the embedded value (EV) rose by 5.5% [5]. Business Segments - The individual insurance channel saw a 22% decline in new premiums, influenced by regulatory changes, but the NBV from this channel grew by 9.5% [2]. - The bancassurance channel experienced a remarkable 111% increase in new premiums, contributing significantly to the overall NBV growth [2]. Investment Strategy - The asset allocation shifted with a decrease in fixed-income assets and an increase in equity investments, reflecting a strategic response to market conditions [4]. - The total investment assets grew by 7.8% since the beginning of the year [4]. Future Outlook - The company anticipates a 17.9% growth in NBV for 2025, supported by a recovery in the bancassurance channel following regulatory changes [2][6]. - The projected EPS for 2025 is adjusted to RMB 3.20, with subsequent years also showing growth [6][12]. Valuation - The target price for the A/H shares has been raised to RMB 49 and HKD 26, respectively, based on a discounted cash flow (DCF) valuation method [6][12].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights that the expansion of bancassurance is driving rapid growth in New Business Value (NBV), with a significant increase in stock investments [1] - The company's net profit for the first half of 2025 is reported at 68 billion yuan, a year-on-year decrease of 8.8%, with a notable increase in NBV by 39.8% on a comparable basis [7][1] - The report indicates a slight adjustment in the forecast for net profit for 2025-2027, now projected at 1297 billion yuan, 1427 billion yuan, and 1638 billion yuan respectively [1] Financial Performance Summary - Total revenue for 2023 is projected at 913,789 million yuan, with a year-on-year growth of 3.8% [1] - The net profit attributable to shareholders for 2023 is expected to be 85,665 million yuan, reflecting a year-on-year decline of 22.8% [1] - The report provides a detailed breakdown of the company's earnings per share (EPS) and price-to-earnings (P/E) ratios, with EPS for 2025 estimated at 7.12 yuan and P/E at 8.50 [1][27] Business Segment Analysis - In the life insurance segment, the NBV margin is reported at 26.1%, with a year-on-year increase of 8.8 percentage points [1] - The property and casualty insurance segment shows a premium income growth of 7.1%, outperforming the industry average of 5.1% [1] - The investment strategy has shifted towards reducing bond and fund allocations while increasing stock investments, resulting in a comprehensive investment return of 3.1%, up by 0.3 percentage points year-on-year [1][26] Market Data - The closing price of the stock is reported at 60.52 yuan, with a market capitalization of approximately 1,102,083.40 million yuan [5] - The company has a price-to-book (P/B) ratio of 1.17 and a price-to-earnings (P/E) ratio of 12.87 [5][24]

Core Viewpoint - The company maintains a "Buy" rating with a target price of HKD 89.80 per share, reflecting a 1.7x P/EV for 2025, supported by stable growth in NBV and EV, and an expected improvement in shareholder returns [1] Group 1: Financial Performance - In H1 2025, the company achieved a net profit attributable to shareholders of USD 2.534 billion, a decrease of 24% year-on-year; however, the after-tax operating profit was USD 3.609 billion, representing a 6% increase [1] - The embedded value (EV) stood at USD 70.853 billion, up 2.6% from the end of the previous year, with a 4.2% contribution from new business value growth and a 4.2% contribution from stable expected returns [1] - The interim dividend for 2025 was set at HKD 0.49 per share, reflecting a 10% year-on-year increase [1] Group 2: New Business Value (NBV) Growth - The company reported a 14% year-on-year increase in NBV for H1 2025, with annualized new premiums rising by 8% and the value ratio improving by 3.4 percentage points to 57.7% [2] - In Hong Kong, NBV grew by 24%, driven by a 35% increase in agent channel NBV due to a 9% growth in active agents and a 30% increase in productivity [2] - In mainland China, NBV decreased by 4%, but if excluding the impact of economic assumptions, it would have increased by 10% [2] Group 3: Shareholder Returns - The operating profit after tax (OPAT) grew steadily, with a 6% increase in H1 2025, primarily due to stable CSM release and positive contributions from operational differences and risk adjustments [3] - The diluted after-tax operating profit per share was USD 0.3391, a 12% increase year-on-year, with the return on equity for shareholders rising by 0.9 percentage points to 16.2% [3] - The company completed a USD 1.6 billion share buyback on July 14, 2025, and returned USD 3.71 billion to shareholders through dividends and buybacks in H1 2025, with free surplus at USD 9.898 billion [3]

Investment Rating - The report maintains a positive outlook on the insurance industry, highlighting strong profit growth driven by investment performance and manageable impacts from economic assumption adjustments [3][4]. Core Insights - The insurance industry is expected to see a significant increase in net profit, with A-share listed insurance companies projected to achieve a total net profit of CNY 347.6 billion in 2024, representing a year-on-year increase of 77.7% [3][5]. - Investment performance is the primary driver of profit growth, contributing 94.5% to the pre-tax profit increase, while total investment income is expected to grow by 110% year-on-year [3][10]. - Economic assumption adjustments have a controllable impact on core indicators, with the investment return rate lowered from 4.5% to 4.0%, and the net value of new business (NBV) expected to decline between 5.4% and 36.2% [3][20][23]. Summary by Sections 1. Investment-Driven Profit Growth - The capital market recovery has significantly boosted the investment performance of insurance companies, leading to a substantial increase in net profit [5][10]. - The total investment income for A-share listed insurance companies is projected to reach CNY 781.1 billion, with a year-on-year growth of 110% [13][10]. 2. Economic Assumption Adjustments - The report indicates a cautious adjustment of economic assumptions, with the investment return rate reduced by 50 basis points to 4.0% [20][22]. - The adjustments are expected to have a limited negative impact on core indicators, with most insurance companies maintaining positive growth in embedded value (EV) [27][30]. 3. Liability Side: NBVM Driving NBV Growth - The NBV growth for listed insurance companies is projected to range from 17.8% to 127% year-on-year, driven by improvements in the new business value margin (NBVM) [3][42]. - The report highlights a mixed performance in new business growth across different companies, influenced by the "reporting and operation integration" policy [47][48]. 4. Asset Side: Strong Investment Performance - The report notes a significant increase in investment assets, with a year-on-year growth of 20.8% to CNY 18.15 trillion by the end of 2024 [3][10]. - The allocation towards bonds and equities has increased, reflecting a positive investment strategy among listed insurance companies [3][10]. 5. Investment Analysis Recommendations - The report recommends continued investment in companies such as New China Life, China Pacific Insurance, China Ping An, AIA, and China Life, based on their strong performance and growth potential [3][10].

Core Viewpoint - The company reported a significant increase in net profit and dividends per share (DPS) for 2024, exceeding expectations, indicating strong financial performance and investor returns [1][2]. Financial Performance - The company achieved a net profit of 26.2 billion yuan in 2024, representing a year-over-year increase of 201.1%, with a fourth-quarter profit of 5.55 billion yuan, showing substantial improvement compared to a loss of 0.83 billion yuan in Q4 2023 [1][2]. - The annual DPS reached 2.53 yuan, up 197.6% year-over-year, with a dividend payout ratio of 30.1%, maintaining a level similar to 2023 [1][2]. New Business Value (NBV) and Premiums - The company reported an NBV of 6.253 billion yuan, reflecting a year-over-year growth of 106.8%, with a first-year premium growth rate of 14.6% [3]. - Long-term first-year premiums reached 27.22 billion yuan, up 15.6% year-over-year, accounting for 70.1% of total premiums [3]. Investment Returns - The company achieved net, total, and comprehensive investment returns of 3.2%, 5.8%, and 8.5%, respectively, with total investment income significantly boosted by fair value changes amounting to 37.5 billion yuan [4]. - The proportion of OCI assets increased to 30.7%, with a notable rise in high-dividend OCI equity investments [4]. Future Outlook - The company is expected to benefit from improved agent quality, product structure optimization, and a higher proportion of equity investments, leading to greater investment return elasticity [5]. - Projected net profits for 2025-2027 are 27.9 billion yuan, 29.3 billion yuan, and 30.8 billion yuan, with corresponding growth rates of 6.5%, 5.1%, and 4.9% [5].

Investment Rating - The report maintains a "Buy" rating for China Life Insurance [1] Core Views - The company's performance in 2024 met expectations, with a significant year-on-year increase in net profit of 108.9% to CNY 106.935 billion, benefiting from a rebound in the equity market [4] - The company's embedded value (EV) grew by 11.2% year-on-year to CNY 1.4 trillion, driven by substantial positive contributions from investment returns [5] - The report anticipates further growth in dividends, with a 51.2% increase in earnings per share to CNY 0.65, resulting in a dividend payout ratio of 17% [4] Financial Performance - In 2024, the company achieved total revenue of CNY 528.567 billion, a year-on-year growth of 30.5% [8] - The net profit for 2024 is projected at CNY 106.935 billion, with a forecasted growth of 5.01% in 2025 [8] - The company's total investment assets reached CNY 6.61 trillion, reflecting a year-on-year increase of 22.1% [6] Investment Analysis - The report highlights a strong investment performance, with total and net investment returns of 5.50% and 3.47%, respectively [6] - The report projects net profits for 2025-2027 at CNY 112.297 billion, CNY 127.893 billion, and CNY 152.342 billion, respectively [6] - The company's price-to-embedded value (P/EV) ratio for 2025 is estimated at 0.70x, indicating potential for further appreciation [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [7] Core Insights - The company reported a net profit of 126.61 billion yuan for 2024, representing a year-on-year increase of 47.8%. The net value of new business (NBV) reached 28.53 billion yuan, up 25.6% year-on-year. The company has adjusted its actuarial assumptions, lowering the investment return rate from 4.5% to 4.0% and the risk discount rate from 9.5% to 8.5%/7.5% [4][13][14] - The company continues to emphasize shareholder returns, proposing a dividend of 2.55 yuan per share for 2024, which is a 5% increase year-on-year [15] Summary by Sections Financial Performance - For 2024, the company achieved a net profit of 1266.07 billion yuan, with a breakdown of profits from various segments: life and health insurance (930 billion yuan, +28%), property insurance (150 billion yuan, +68%), banking (258 billion yuan, -4%), asset management (-119 billion yuan, loss narrowed), and financial empowerment (129 billion yuan, +528%) [14] - The operating profit for 2024 was 1218.62 billion yuan, reflecting a 9.1% increase year-on-year [14] New Business Value (NBV) - The NBV for 2024 was 285.34 billion yuan, with a year-on-year growth of 25.6%. The first-year premium used for calculating NBV was 1540.26 billion yuan, down 7.1% year-on-year [15] - The NBV margin improved to 22.7%, an increase of 3.5 percentage points year-on-year [15] Actuarial Assumptions and EV Growth - The company's actuarial assumptions adjustments led to a decrease in the expected value (EV) growth, with the EV for life and health insurance at 8350.93 billion yuan by the end of 2024, down 13.1% due to these adjustments [15] - The company’s EV based on 2023 assumptions was 9606.08 billion yuan, reflecting a 15.6% increase from the beginning of the year [15] Dividend Policy - The proposed dividend of 2.55 yuan per share for 2024 indicates a commitment to shareholder returns, with a payout ratio of 37.9% of the operating profit [15] Future Projections - The company forecasts insurance business revenues of 575.68 billion yuan, 600.48 billion yuan, and 628.27 billion yuan for 2025, 2026, and 2027 respectively, with corresponding growth rates of 4.4%, 4.3%, and 4.6% [17] - Projected net profits for the same years are 141.39 billion yuan, 164.21 billion yuan, and 193.67 billion yuan, with growth rates of 11.7%, 16.1%, and 17.9% respectively [17]